Genetic Screening Processor (GSP); PerkinElmer Part Number= 2021-0010 Intended for in vitro qu...
FDA Device Recall #Z-1107-2017 — Class II — January 5, 2017
Recall Summary
| Recall Number | Z-1107-2017 |
| Classification | Class II — Moderate risk |
| Date Initiated | January 5, 2017 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | PerkinElmer Life and Analytical Sciences, Wallac, OY |
| Location | Turku, N/A |
| Product Type | Devices |
| Quantity | 24 instruments and 3 spare disk remover modules |
Product Description
Genetic Screening Processor (GSP); PerkinElmer Part Number= 2021-0010 Intended for in vitro quantitative and qualitative determination of analytes in body fluids.
Reason for Recall
The firm became aware that the ball bushing axels are defective in the GSP instrument. During exposure to humid conditions, there is a risk that the axle material will corrode. Deterioration of the axle can be observed as deposits of corrosion on the defective axles. Ball bushing axles may corrode and corrosion particle may cause contamination in the wells or the corrosion will cause movement issues and possibly spillage and causing contamination of the plate wells.
Distribution Pattern
MA, SC, TX, AL OUS: China, Mexico, Peru, Morocco, Italy, Finland, Ecuador, Brazil
Lot / Code Information
Serial Numbers: 20210239 20210243 20210244 20210245 20210246 20210247 20210248 20210249 20210250 20210251 20210252 20210253 20210254 20210255 20210256 20210257 20210258 20210259 20210260 20210261 20210262 20210263 20210264 20210265
Other Recalls from PerkinElmer Life and Analytical Scien...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1239-2019 | Class II | AutoDELFIA¿ hCG Kit, In Vitro Diagnostic for th... | Jan 10, 2019 |
| Z-1237-2019 | Class II | DELFIA¿ hCG Kit, In Vitro Diagnostic for the de... | Jan 10, 2019 |
| Z-1238-2019 | Class II | AutoDELFIA¿ hCG Kit, In Vitro Diagnostic for th... | Jan 10, 2019 |
| Z-1541-2018 | Class II | Specimen Gate Screening Center, Part Number 500... | Nov 17, 2017 |
| Z-1692-2018 | Class II | NeoBase Succinylacetone Assay Solution, Product... | Nov 2, 2017 |
Frequently Asked Questions
Sterility recalls for medical devices vary in severity. If you have already had a procedure using a potentially non-sterile device, contact your healthcare provider immediately — you may need monitoring for signs of infection. Symptoms to watch for include fever, redness or swelling at the surgical site, unusual pain, or discharge. For devices that have not yet been used, they should be quarantined and returned to the manufacturer per the recall notice. Non-sterile implants can cause serious infections; early detection and treatment are critical.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.